These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36864784)
21. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345 [TBL] [Abstract][Full Text] [Related]
22. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988 [TBL] [Abstract][Full Text] [Related]
23. Immune microenvironment of gliomas. Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634 [TBL] [Abstract][Full Text] [Related]
24. GDNF mediates glioblastoma-induced microglia attraction but not astrogliosis. Ku MC; Wolf SA; Respondek D; Matyash V; Pohlmann A; Waiczies S; Waiczies H; Niendorf T; Synowitz M; Glass R; Kettenmann H Acta Neuropathol; 2013 Apr; 125(4):609-20. PubMed ID: 23344256 [TBL] [Abstract][Full Text] [Related]
25. Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1. Schachtele SJ; Hu S; Sheng WS; Mutnal MB; Lokensgard JR Glia; 2014 Oct; 62(10):1582-94. PubMed ID: 24890099 [TBL] [Abstract][Full Text] [Related]
26. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia. Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121 [TBL] [Abstract][Full Text] [Related]
27. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas. Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077 [TBL] [Abstract][Full Text] [Related]
28. The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. Najafi S; Majidpoor J; Mortezaee K Biomed Pharmacother; 2023 May; 161():114436. PubMed ID: 36841031 [TBL] [Abstract][Full Text] [Related]
29. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396 [TBL] [Abstract][Full Text] [Related]
30. Oncolytic virus in gliomas: a review of human clinical investigations. Carpenter AB; Carpenter AM; Aiken R; Hanft S Ann Oncol; 2021 Aug; 32(8):968-982. PubMed ID: 33771666 [TBL] [Abstract][Full Text] [Related]
31. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908 [TBL] [Abstract][Full Text] [Related]
35. Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth. Wang J; Leavenworth JW; Hjelmeland AB; Smith R; Patel N; Borg B; Si Y; King PH Glia; 2019 Dec; 67(12):2424-2439. PubMed ID: 31400163 [TBL] [Abstract][Full Text] [Related]
36. Correlation of immune phenotype with IDH mutation in diffuse glioma. Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337 [TBL] [Abstract][Full Text] [Related]
37. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Ghajar-Rahimi G; Kang KD; Totsch SK; Gary S; Rocco A; Blitz S; Kachurak K; Chambers MR; Li R; Beierle EA; Bag A; Johnston JM; Markert JM; Bernstock JD; Friedman GK Pharmacol Ther; 2022 Nov; 239():108193. PubMed ID: 35487285 [TBL] [Abstract][Full Text] [Related]
38. Tumour-derived CSF2/granulocyte macrophage colony stimulating factor controls myeloid cell accumulation and progression of gliomas. Sielska M; Przanowski P; Pasierbińska M; Wojnicki K; Poleszak K; Wojtas B; Grzeganek D; Ellert-Miklaszewska A; Ku MC; Kettenmann H; Kaminska B Br J Cancer; 2020 Aug; 123(3):438-448. PubMed ID: 32390004 [TBL] [Abstract][Full Text] [Related]
39. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment. Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095 [TBL] [Abstract][Full Text] [Related]
40. Synergistic Toll-like Receptor 3/9 Signaling Affects Properties and Impairs Glioma-Promoting Activity of Microglia. Huang Y; Zhang Q; Lubas M; Yuan Y; Yalcin F; Efe IE; Xia P; Motta E; Buonfiglioli A; Lehnardt S; Dzaye O; Flueh C; Synowitz M; Hu F; Kettenmann H J Neurosci; 2020 Aug; 40(33):6428-6443. PubMed ID: 32631940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]